Business Context and Reporting Period
Sotera Health Company filed this Form 8-K on May 27, 2021, reporting the results of its 2021 Annual Meeting of Stockholders held that day. The filing does not provide operating or financial-period results.
Meeting Participation and Voting Results
- Holders of 274,971,050 common shares participated in person or by proxy, representing 97.2% of voting power as of the April 1, 2021 record date.
- A quorum was present.
Election of Class I Directors
| Nominee | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Constantine S. Mihas | 247,631,027 | 24,611,957 | 66,453 | 2,661,613 |
| James C. Neary | 247,630,726 | 24,612,258 | 66,453 | 2,661,613 |
| Michael B. Petras, Jr. | 253,350,287 | 18,950,434 | 8,716 | 2,661,613 |
| David E. Wheadon | 266,303,968 | 5,939,017 | 66,452 | 2,661,613 |
All four nominees were elected to serve until the 2024 annual meeting and until their successors are elected and qualified.
Ratification of Independent Auditor
| Proposal | For | Against | Abstain |
|---|---|---|---|
| Ratification of Ernst & Young LLP for fiscal year 2021 | 274,841,142 | 122,505 | 7,403 |
Stockholders ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. There were no broker non-votes on this proposal.
Financial Metrics and Material Changes
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating metrics. It does not report material changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
The filing contains no management outlook, risk updates, contingencies, or unusual financial items. The principal disclosed corporate actions are the election of four directors and auditor ratification.
Investor Verification Points
- Confirm the four elected Class I directors and their terms through the 2024 annual meeting.
- Review voting margins and broker non-votes, particularly for the director elections.
- Confirm Ernst & Young LLP’s appointment for the fiscal year ending December 31, 2021.
- Consult the April 15, 2021 definitive proxy statement for the detailed background and recommendations relating to the proposals.